tiprankstipranks
Trending News
More News >
Myriad Genetics (MYGN)
NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Statistics & Valuation Metrics

Compare
392 Followers

Total Valuation

Myriad Genetics has a market cap or net worth of $509.74M. The enterprise value is $531.30M.
Market Cap$509.74M
Enterprise Value$531.30M

Share Statistics

Myriad Genetics has 92,177,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding92,177,380
Owned by Insiders4.46%
Owned by Institutions24.38%

Financial Efficiency

Myriad Genetics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -14.53%.
Return on Equity (ROE)-0.18
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-14.53%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee310.22K
Profits Per Employee-47.15K
Employee Count2,700
Asset Turnover0.82
Inventory Turnover9.17

Valuation Ratios

The current PE Ratio of Myriad Genetics is -9.76. Myriad Genetics’s PEG ratio is -0.22.
PE Ratio-9.76
PS Ratio0.00
PB Ratio0.65
Price to Fair Value1.77
Price to FCF-13.00
Price to Operating Cash Flow-72.12
PEG Ratio-0.22

Income Statement

In the last 12 months, Myriad Genetics had revenue of 837.60M and earned -127.30M in profits. Earnings per share was -1.41.
Revenue837.60M
Gross Profit585.40M
Operating Income-123.50M
Pretax Income-123.50M
Net Income-127.30M
EBITDA-59.50M
Earnings Per Share (EPS)-1.41

Cash Flow

In the last 12 months, operating cash flow was -6.40M and capital expenditures -29.40M, giving a free cash flow of -35.80M billion.
Operating Cash Flow-6.40M
Free Cash Flow-35.80M
Free Cash Flow per Share-0.39

Dividends & Yields

Myriad Genetics pays an annual dividend of $1.75, resulting in a dividend yield of ―
Dividend Per Share$1.75
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.53
52-Week Price Change-77.39%
50-Day Moving Average5.28
200-Day Moving Average13.04
Relative Strength Index (RSI)60.69
Average Volume (3m)1.93M

Important Dates

Myriad Genetics upcoming earnings date is Jul 31, 2025, TBA (Confirmed).
Last Earnings DateMay 6, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend DateJul 01, 2009

Financial Position

Myriad Genetics as a current ratio of 1.82, with Debt / Equity ratio of 22.36%
Current Ratio1.82
Quick Ratio1.65
Debt to Market Cap0.03
Net Debt to EBITDA-0.64
Interest Coverage Ratio-44.11

Taxes

In the past 12 months, Myriad Genetics has paid 3.80M in taxes.
Income Tax3.80M
Effective Tax Rate-0.03

Enterprise Valuation

Myriad Genetics EV to EBITDA ratio is -21.51, with an EV/FCF ratio of -33.33.
EV to Sales1.53
EV to EBITDA-21.51
EV to Free Cash Flow-33.33
EV to Operating Cash Flow-147.13

Balance Sheet

Myriad Genetics has $91.80M in cash and marketable securities with $157.60M in debt, giving a net cash position of $65.80M billion.
Cash & Marketable Securities$91.80M
Total Debt$157.60M
Net Cash$65.80M
Net Cash Per Share$0.71
Tangible Book Value Per Share$1.68

Margins

Gross margin is 70.01%, with operating margin of -14.74%, and net profit margin of -15.20%.
Gross Margin70.01%
Operating Margin-14.74%
Pretax Margin-14.74%
Net Profit Margin-15.20%
EBITDA Margin-7.10%
EBIT Margin-14.41%

Analyst Forecast

The average price target for Myriad Genetics is $8.64, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$8.64
Price Target Upside53.46% Upside
Analyst ConsensusHold
Analyst Count14
Revenue Growth Forecast7.38%
EPS Growth Forecast60.45%

Scores

Smart Score3
AI Score44.5
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis